Synthorx (NASDAQ:THOR) Upgraded to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research report report published on Saturday, Zacks.com reports. Zacks Investment Research currently has $22.00 price target on the medical instruments supplier’s stock.

According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “

Several other research firms have also weighed in on THOR. HC Wainwright set a $30.00 price objective on Synthorx and gave the stock a buy rating in a research report on Wednesday, September 18th. ValuEngine lowered Synthorx from a buy rating to a hold rating in a research report on Wednesday, September 25th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Synthorx has an average rating of Buy and an average target price of $24.33.

Shares of NASDAQ THOR traded up $1.89 during trading hours on Friday, reaching $16.03. 243,100 shares of the stock were exchanged, compared to its average volume of 93,994. The stock’s fifty day simple moving average is $14.41 and its 200 day simple moving average is $15.40. Synthorx has a 52 week low of $11.00 and a 52 week high of $23.53. The firm has a market capitalization of $526.26 million and a price-to-earnings ratio of -2.43.

Synthorx (NASDAQ:THOR) last posted its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.12. On average, research analysts predict that Synthorx will post -1.81 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of THOR. Morgan Stanley increased its position in Synthorx by 9,312.2% in the 2nd quarter. Morgan Stanley now owns 123,112 shares of the medical instruments supplier’s stock valued at $1,663,000 after buying an additional 121,804 shares in the last quarter. BlackRock Inc. increased its position in Synthorx by 25.7% in the 2nd quarter. BlackRock Inc. now owns 543,305 shares of the medical instruments supplier’s stock valued at $7,341,000 after buying an additional 111,165 shares in the last quarter. Citadel Advisors LLC bought a new stake in Synthorx in the 2nd quarter valued at about $787,000. Russell Investments Group Ltd. bought a new stake in Synthorx in the 3rd quarter valued at about $800,000. Finally, Vanguard Group Inc. increased its position in Synthorx by 8.4% in the 2nd quarter. Vanguard Group Inc. now owns 336,963 shares of the medical instruments supplier’s stock valued at $4,552,000 after buying an additional 26,085 shares in the last quarter. 65.66% of the stock is owned by institutional investors and hedge funds.

Synthorx Company Profile

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

See Also: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on Synthorx (THOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.